First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

• Paolo Ghia,
• Carolyn Owen,
• John N. Allan,
• Jacqueline C. Barrientos,
• Paul M. Barr,
• Chunxue Shi,
• Anita Szoke,
• Christopher Abbazio,
• Gabriel S. Krigsfeld,
• Jan A. Burger

Affiliations

Paolo Ghia

Division of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy

Carolyn Owen

Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada

John N. Allan

Weill Cornell Medicine New York New York USA

Jacqueline C. Barrientos

Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Miami Florida USA

Paul M. Barr

Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA

Chunxue Shi

Biostatistics, Everest Clinical Research Owings Mills Maryland USA

Anita Szoke

AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA

Christopher Abbazio

AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA

Gabriel S. Krigsfeld

AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA

Jan A. Burger

Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA